Array stock: buy or sell?
July 30th, 2019
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.
Should I buy Array stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. That's why is so important to define your own trading plan that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, 2 buy setups are elegible for Array stock right now:
|New all-time high||Yes|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Array BioPharma stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we collected 15 ratings published for ARRY stock in the last 30 days.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-7-12||JPMorgan Chase & Co.||Overweight||Neutral|
|2019-6-18||Svb Leerink||Outperform||Market Perform|
|2019-6-18||Leerink Swann||Outperform||Market Perform|
|2019-6-18||Goldman Sachs Group||n/a||Neutral|
|2019-6-17||Wells Fargo & Co||Outperform||Market Perform|
|2019-6-17||Piper Jaffray Companies||Overweight||Neutral|
|2019-6-17||Jefferies Financial Group||Buy||Hold|
|2019-5-21||Piper Jaffray Companies||n/a||Overweight|
|2019-3-14||JPMorgan Chase & Co.||Positive||Overweight|
|2019-1-15||Piper Jaffray Companies||Overweight||Positive|
Array stock analysis
Array shares peaked new all time highs back again on Jul/30, setting highs to $47.98. Shares closed at $47.85 and stayed stable 0.00%.
After climbing to all-time highs several times in past weeks, Array BioPharma stayed stable 0.00% to $47.85. ARRY broke out again over $47.01 after a 1.68% correction started on July. On May ARRY price bounced up over the SMA of 100 days demonstrating to be a significant support for this stock.
Shares of Array ended this week at $47.85 after marking a new all time high ($47.98) and gained a slightly good 1.18%. By mid June ARRY rocketed an extraordinary 35.95% in just one week.
Price pattern shows an uptrend with two rising tops and bottoms, and now finally trading above the $47.05 resistance. Early February, SMA20w and SMA40w crossed up triggering a rise of 149.22%. Late December 2018 ARRY price bounced up over the SMA of 40 weeks that acted as support stopping new slides.
Array stock price history
Array IPO was on November 30th, 2000 at $8.75 per share1. Since then, ARRY stock grew a 446.90%, with an average of 24.80% per year. If you had invested $1,000 in Array stock in 2000, it would worth $4,469.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Array stock historical price chart
ARRY stock reached all-time highs on Jul/30 with a price of $47.98.
Array stock price target is $36.80How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' ARRY stock price predictions in the hope that they will be met as they may be wrong and not met. We found 9 price forecasts for Array stock published in the last month:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-7-12||JPMorgan Chase & Co.||Downgrades||$29.00||$48.00||65.5%|
|2019-6-18||Goldman Sachs Group||Raises Target||$27.00||$38.00||40.7%|
|2019-5-22||SunTrust Banks||Raises Target||n/a||$32.00||-|
|2019-5-21||Piper Jaffray Companies||Reiterates||$28.00||$35.00||25%|
|2019-3-14||JPMorgan Chase & Co.||Reiterates||$18.00||$29.00||61.1%|
|2019-1-15||Piper Jaffray Companies||Reiterates||n/a||$28.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, Array BioPharma missed the estimates of the experts and posted a bloodcurdling EPS of $-0.05 per share when experts were expecting $-0.16.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Array BioPharma annual revenues rocketed an extraordinary 15.19% to $173.77 M USD from $150.85 marked in 2017. When comparing 2018 vs 2017, however, profit margin (that is, the net income divided by revenues) slipped a -7.36% to -84.79%. To have an up to date picture of the financial situation of Array, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2018-Q4 that can be compared to 2018 fiscal year results. Annual Array TTM sales up to December 2018 were $241.26 and earnings were $-111.47 million USD. When comparing this TTM figures with the last reported annuality, we can review Array business evolution since June 2018: Annual turnover up to December, compared to lastest yearly report, boosted a dazzling 38.84%. Regarding profit margin, Array climbed 38.59% to -84.79%
|2013||$70 M||-||$-61.94 M-89.0%||-|
|2014||$42 M||-39.52%||$-85.26 M-202.6%||37.65%|
|2015||$52 M||23.36%||$9.37 M18.0%||-110.99%|
|2016||$138 M||165.62%||$-92.84 M-67.3%||-1,090.93%|
|2017||$151 M||9.41%||$-116.82 M-77.4%||25.83%|
|2018||$174 M||15.19%||$-147.35 M-84.8%||26.13%|
|TTM||$241 M||38.84%||$-111.47 M-46.2%||-24.35%|
Quarterly financial resultsArray reported $82.55 million in revenues for 2018-Q4, a 45.05% up compared to previous quarter. Reported quarter earnings marked $-11.36 M with a profit margin of -13.76%. Profit margin boosted a 29.83% compared to previous quarter when profit margin was -43.60%. When comparing turnover to same quarter last year, Array BioPharma sales marked a super good growth and climbed a 95.53%. Looking back to recent quarterly results, Array posted 2 positive quarters in a row.
|2017-Q1||$33 M||-||$-35.32 M-106.1%||-|
|2017-Q2||$34 M||1.50%||$-29.59 M-87.6%||-16.22%|
|2017-Q3||$30 M||-11.94%||$-37.99 M-127.7%||28.40%|
|2017-Q4||$42 M||41.93%||$-34.05 M-80.7%||-10.37%|
|2018-Q1||$66 M||57.20%||$-22.85 M-34.4%||-32.90%|
|2018-Q2||$35 M||-46.60%||$-52.45 M-148.0%||129.52%|
|2018-Q3||$57 M||60.59%||$-24.81 M-43.6%||-52.69%|
|2018-Q4||$83 M||45.05%||$-11.36 M-13.8%||-54.21%|
Array ownershipWhen you are planning to buy a stock, it's worth to have a look its ownership structure.
Array shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.38% of all shares.
Bearish positions for ARRY stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Array:
|Market cap||$10.6 B|
|Total shares||221.8 M|
|Float shares||220.9 M|
|- Institutional holdings (%)||100.7%|
|- Insider holdings (%)||0.4%|
|Shares in short selling||0.0%|
|Tuesday, July 30th, 2019|
|Day range||$47.84 - $47.98|
|Average true range||$0.38|
|50d mov avg||$39.37|
|100d mov avg||$31.28|
|200d mov avg||$24.31|
Array performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We selected as the bechmarking frame for Array stock.